Eiger biopharmaceuticals, inc. (EIGR)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-

-

-

-

-

-

-

-

-

-

-

-11,146

-11,239

-

-11,370

-13,201

-9,748

-

-

-

-

-

-

-

-

Net loss

-15,239

-16,920

-18,616

-17,527

-17,189

-16,501

-17,144

-9,915

-8,831

-

-

-

-

-

-

-

-

-

-

-

-16,746

-

-

-

-7,162

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

36

27

14

14

13

20

12

11

11

11

11

10

9

-

-

-

-

-359

218

77

76

43

50

34

26

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

5

4

-

-

-

-

-

-

-

-

Amortization of debt securities discounts

38

77

198

71

121

169

212

42

3

-10

-10

20

53

-

-

-

-

-

-4

-42

-148

-230

-114

-36

-13

Non-cash interest expense

191

188

183

175

177

199

175

120

98

100

95

98

73

0

0

0

685

-

1,271

235

301

198

131

0

59

Amortization of operating lease right-of-use assets

115

119

102

100

97

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued under Product Development Agreement

53

56

59

55

56

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,629

1,348

1,649

1,487

1,195

1,511

1,172

1,321

1,003

1,020

953

946

1,324

1,439

1,239

174

338

-2,955

-18

1,098

2,103

1,141

911

748

519

Change in fair value of obligation to issue shares to Eiccose

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

204

-

-

-

-

-

-

-

-

Change in fair value of warrants liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

165

-

-

-

-

0

0

0

183

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

-7

1

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

108

5

4

-

-62

-23

1

Change in operating assets and liabilities:
Prepaid expenses and other current assets

-332

731

1,426

439

1,102

-372

379

868

-95

-71

-186

440

-52

-331

-248

686

-433

-

-

-

-

-

-

-

-

Other assets

1,270

-877

790

-108

2,270

47

99

1

-23

246

-15

-43

-19

1

-3

-10

101

-

-

-

-

-

-

-

-

Accounts payable

2,459

-2,594

1,855

1,630

-307

-687

2,079

1,413

-158

-984

-301

1,281

548

-1,436

2,836

-4,823

4,122

-

-

-

-

-

-

-

-

Accrued liabilities

-5,893

2,851

2,686

-596

669

2,735

307

-72

-860

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-115

-115

-109

-106

-100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

-

-

-

-

-

-

-

-

-

-

344

312

-1,739

-

-263

-469

185

-

-

-

-

-

-

-

-

Other long term liabilities

-

-

-

-

-

-2

21

143

50

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-17,740

-14,971

-14,591

-15,170

-18,882

-12,502

-13,707

-7,890

-8,572

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Prepaid expenses and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-175

-546

-1,518

2,171

143

143

403

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,498

1,721

-2,160

2,025

899

-208

219

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-11,006

-

-7,301

-15,818

-3,713

27,599

-9,377

-12,591

-14,765

-9,885

-6,325

-6,502

-6,547

Purchase of debt securities available-for-sale

23,933

0

36,020

58,304

1,943

-

-

-

-

1,991

4,983

8,287

9,263

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,998

50,594

37,817

250

Proceeds from maturities of debt securities available-for-sale

24,608

35,000

11,221

15,250

18,800

14,000

4,500

0

9,750

11,500

14,825

13,770

6,930

-

-

-

-

-

8,000

12,525

49,802

12,010

7,500

3,750

6,950

Cash received from merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

28,018

-

-

-

-

-

-

-

-

Purchase of property and equipment

23

381

75

18

1

-

-

-

-

0

0

21

23

5

33

12

8

-190

79

62

94

190

279

58

212

Net cash provided by investing activities

652

34,619

-24,874

-43,072

16,856

9,070

-7,750

-40,155

9,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

269

4

4

-

-

-

-

Net cash provided (used in) by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,356

-

-33

-12

28,010

-70,413

8,190

12,467

49,712

9,822

-43,373

-34,125

6,488

Proceeds from borrowings in connection with term loan, net of issuance costs

-

0

0

0

6,627

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of accrued exit fee and second amendment fee

-

0

0

0

913

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs paid in connection with common stock offerings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

265

2,746

83

4,567

Repayment of term loan

-

0

0

0

1,667

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon stock option exercises

30

338

379

62

65

-

-

-

-

-

-

-

-

0

0

32

7

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon private placement, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

32,108

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon ESPP purchase

83

0

71

0

59

0

62

0

34

0

85

0

57

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock upon offering at-the-market, net of issuance costs

231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

147

636

450

43,774

204

50,600

Proceeds from issuance of common stock upon warrants exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

-

-

-

-

-

-

-

-

Net cash provided by financing activities

344

319

450

53,256

4,171

47,767

5,061

48,121

34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-16,744

19,967

-39,015

-4,986

2,145

44,335

-16,396

76

1,212

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

57

-

18,229

32

32,122

24,158

-11,762

147

636

131

50,694

121

46,033

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-13,305

-

10,895

-15,798

56,419

-18,655

-12,949

23

35,583

68

996

-40,506

45,974

Conversion of warrant liability to common stock upon private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,050

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon private placement, net of issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

32,108

-

-

-

-

-

-

-

-

Non-cash net liabilities assumed in reverse merger

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

671

-

-

-

-

-

-

-

-

Conversion of convertible promissory note to common stock upon private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,438

0

0

22,567

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock upon reverse merger

-

-

-

-

-

-

-

-

-

-

-

-

-

16,438

0

0

6,129

-

-

-

-

-

-

-

-

Interest paid

694

694

702

465

777

546

467

342

297

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-